Victory Capital Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Victory Capital Management’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,625	Closed	-$4K	–	2792
2022 Q1	$4K	Buy	1,625 +138	+9%	+$868	﹤0.01%	2716
2021 Q4	$8K	Buy	1,487 +28	+2%	+$238	﹤0.01%	2742
2021 Q3	$16K	Buy	1,459 +94	+7%	+$1.18K	﹤0.01%	2740
2021 Q2	$23K	Buy	1,365 +333	+32%	+$6.31K	﹤0.01%	2704
2021 Q1	$27K	Buy	1,032 +178	+21%	+$8.09K	﹤0.01%	2706
2020 Q4	$31K	Buy	854 +96	+13%	+$3.47K	﹤0.01%	2484
2020 Q3	$27K	Sell	758 -14	-2%	-$609	﹤0.01%	2418
2020 Q2	$33K	Buy	772 +210	+37%	+$14.2K	﹤0.01%	2420
2020 Q1	$44K	Buy	+562	New	+$45K	﹤0.01%	2833
2019 Q4	–	Sell	-441	Closed	-$33K	–	3552
2019 Q3	$33K	Buy	+441	New	+$33.9K	﹤0.01%	2873

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Victory Capital Management's EVFM Position: Q2 2022 in Review

Victory Capital Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 1,625 shares — an estimated $4K sold.

Victory Capital Management first reported a position in EVFM in Q3 2019 and held it in 10 quarters. The position peaked at $44K in Q1 2020. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

Victory Capital Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Victory Capital Management sold 1,625 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $4K.
Victory Capital Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2019 and held it in 10 quarters.
Victory Capital Management's Evofem Biosciences, Inc. Common Stock position peaked at $44K in Q1 2020.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Victory Capital Management's 13F filing for Q2 2022, filed 1 Aug 2022.